On watch for clear above 49.87. Technical 83% chance bullish at foxchart.
The stock deserves its run. It is well managed, with decent yield, and hasn't done much in the last two years. The last time it was at current high was in 2015.
Cut us a break Paul...... disgruntle IT worker and or staff.
There are those who watch only shareholder value. I have spent considerable time inside Abbott and the decision to outsource accounting, admin and IT functions to Wipro (through Nancy Berce) is a disaster. It has hobbled the ability of the rank and file (fine people) to DO THEIR JOB efficiently and make their numbers. Tickets are not resolved quickly, passed around and around for days if not weeks. Everybody thinks that the IT staffers are just a bunch of know-nothing geeks and that Noida and Pune can manage everything with a phone call or remote. No true. All of Abbott's business IS computer based and deserves respect. So the shareholder value crowd here .... take a look inside the Abbott container. It has been poisoned.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is 0.8 In other words, the correlation coefficient of the other stocks
Folks, ole Tex is telling you now to sell this stock. There's no question she falls from here. We've been running the numbers and this stock is due for a pullback. You all know Ole Tex has been right almost every time. Don't miss this opportunity. Happy trading
(AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....The next big player in the making here ! GLTA
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
On Friday, there was a new Medical Devices report posted by The Wall Street Transcript. It has seven new long-form interviews with analysts and executives.